JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Aditxt Inc. (ADTX) announced that its subsidiary Pearsanta Inc. has engaged Spartan Capital Securities as lead underwriter for a planned initial public offering. Spartan will serve as exclusive financial advisor and bookrunner for the offering.
The proposed IPO aims to support clinical validation and commercial rollout of Pearsanta’s diagnostic tests for early detection of cancers and other diseases. The tests utilize Pearsanta’s Mitomic mitochondrial DNA platform technology and operate through CLIA-certified, CAP-accredited laboratory infrastructure.
"We view the proposed IPO as a critical first step in advancing Pearsanta’s mission of addressing cancer through early detection—and ultimately, prevention," said Amro Albanna, co-founder and CEO of Aditxt.
Pearsanta focuses on precision health through advanced diagnostic technologies. Its Mitomic Technology Platform uses mitochondrial DNA properties to detect cancer and other diseases through non-invasive, blood-based liquid biopsy tests, according to the company.
The IPO represents part of Aditxt’s Acquire, Build, and Capitalize strategy designed to accelerate growth of health innovation companies. Aditxt operates as a social innovation platform with programs focused on immune health and precision health.
The press release includes standard disclaimers stating it does not constitute an offer to sell securities and that any offers will comply with Securities Act of 1933 registration requirements.